IQVIA (NYSE:IQV) Reaches New 52-Week High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $277.40 and last traded at $273.6540, with a volume of 74125 shares. The stock had previously closed at $270.09.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Royal Bank Of Canada boosted their price target on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Morgan Stanley boosted their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $248.00.

IQVIA Price Performance

The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a 50 day moving average of $245.20 and a two-hundred day moving average of $200.94. The firm has a market cap of $44.64 billion, a P/E ratio of 33.66, a PEG ratio of 2.31 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insider Buying and Selling

In related news, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 15,581 shares of company stock worth $3,796,021. Insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

Several hedge funds have recently added to or reduced their stakes in the business. Korea Investment CORP acquired a new stake in IQVIA during the 2nd quarter worth $13,918,000. Deutsche Bank AG bought a new position in shares of IQVIA during the 2nd quarter worth approximately $143,074,000. BlackRock Inc. acquired a new stake in IQVIA in the 2nd quarter valued at $2,811,292,000. Focus Partners Advisor Solutions LLC bought a new stake in IQVIA during the second quarter worth about $976,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $1,552,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.